Aditum Bio
Overview
Aditum Bio is a venture capital firm that focuses on acquiring and developing biotechnology assets. The firm's model involves in-licensing promising drug candidates and creating new companies to advance them through Phase II clinical trials.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Oblenio Bio | Jun 2026 | Series B | Co-investor |
| Via Nova Therapeutics | Sep 2021 | Series A | Lead |
| Kalexo Bio | Sep 2025 | Corporate Funding | Lead |
| EmbarkNeuro | Jun 2021 | Seed | Lead |
| Motric Bio | Nov 2021 | Seed | Lead |
Key People
Joe Jimenez
Co-Founder and Managing Director
Josh Gertsman
Partner
Praveena Kandula
Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Aditum Bio based?
Aditum Bio is headquartered in Oakland, California, United States.
When was Aditum Bio founded?
Aditum Bio was founded in 2019.
How many portfolio companies does Aditum Bio have?
Aditum Bio has 5 portfolio companies in Caplight's dataset.
What are some companies in Aditum Bio's portfolio?
Portfolio companies visible on Caplight include Oblenio Bio, Via Nova Therapeutics, Kalexo Bio, EmbarkNeuro, Motric Bio.
What was Aditum Bio's most recent investment shown here?
Aditum Bio's most recent investment in this portfolio sample was in Oblenio Bio in 2026.
What sectors does Aditum Bio focus on?
Aditum Bio focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Aditum Bio focus on?
Aditum Bio typically invests at the Early stage.
What is Aditum Bio's AUM?
Aditum Bio's assets under management are estimated at over $135.0M.